secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-08-13T20:02:19+00:00
Accession:  0001728117-26-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Q2 net income $16.9M; NDA on track Sept 2026; reacquires seralutinib rights
--------------------------------------------------------------------------------

- Q2 2026 net income $16.9M vs net loss $38.3M in Q2 2025; revenue $9.2M from Chiesi collaboration.
- NDA submission for seralutinib in PAH on track for Sept 2026; FDA feedback from Pre-NDA Type B meeting; potential approval decision Q3 2027.
- Reacquired worldwide rights to seralutinib from Chiesi; no upfront cash, Chiesi gets capped royalty and milestone payments.
- Exchanged $181.1M of 5.00% 2027 notes for $65.2M new 7.50% 2030 notes, reducing debt by ~$115.9M; 2027 notes now ~$18.9M.
- Cash $57.0M at June 30, 2026; expected to fund operations into Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/0001728117-26-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer